{"title":"Practical considerations in transfusion techniques during anesthesia.","authors":"R J Saunders, J M Calkins","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75737,"journal":{"name":"Contemporary anesthesia practice","volume":"6 ","pages":"169-81"},"PeriodicalIF":0.0,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17873515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sevoflurane is nonexplosive and, in clinically useful concentrations, nonflammable. It is relatively chemically inert in that it can be stored without preservative, and undergoes limited dehydrofluorination in moist alkali. It does not sensitize the heart to epinephrine or cause alterations of hematologic or serum clinical chemistry values after repeated exposures in animals or in man after a single exposure. It depresses respiration and cardiovascular functions in experimental animals and man, but less than halothane. It is metabolized to a limited extent, releasing subnephrotoxic amounts of fluoride ion. Sevoflurane warrants further testing in man.
{"title":"Sevoflurane: an experimental anesthetic.","authors":"D A Holaday","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Sevoflurane is nonexplosive and, in clinically useful concentrations, nonflammable. It is relatively chemically inert in that it can be stored without preservative, and undergoes limited dehydrofluorination in moist alkali. It does not sensitize the heart to epinephrine or cause alterations of hematologic or serum clinical chemistry values after repeated exposures in animals or in man after a single exposure. It depresses respiration and cardiovascular functions in experimental animals and man, but less than halothane. It is metabolized to a limited extent, releasing subnephrotoxic amounts of fluoride ion. Sevoflurane warrants further testing in man.</p>","PeriodicalId":75737,"journal":{"name":"Contemporary anesthesia practice","volume":"7 ","pages":"45-59"},"PeriodicalIF":0.0,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17934126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Balanced salt solutions in massive trauma.","authors":"C J Carrico, R V Maier","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75737,"journal":{"name":"Contemporary anesthesia practice","volume":"6 ","pages":"57-83"},"PeriodicalIF":0.0,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17398316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recent research has led to the development of a new family of synthetic narcotic fentanyl derivatives. Two of these, sufentanil and alfentanil, are already in clinical use abroad and are presently under clinical investigation in the United States. Sufentanil is more potent than fentanyl and is claimed to have fewer side effects and less variability in patient cardiovascular responses under stress. It appears that its primary application will be for high-dose narcotic anesthesia in patients with cardiovascular disease. Alfentanil has a shorter duration of action and is claimed to have less postoperative ventilatory depression than fentanyl. It is being recommended for use via continuous intravenous infusion. It will probably become a popular anesthetic agent for outpatient and short surgical procedures. It should be remembered that at this time very little information concerning these agents is in print. Most of the research has been done by a handful of investigators and much has not been published in peer review publications. Based on the clinical impressions of our European colleagues, one can say that these agents should be as safe and as reliable as fentanyl, but any clinically significant advantages over their parent compound, especially in the case of sufentanil, will have to await more widespread use and controlled investigation.
{"title":"New narcotics in anesthesia.","authors":"J D Borel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent research has led to the development of a new family of synthetic narcotic fentanyl derivatives. Two of these, sufentanil and alfentanil, are already in clinical use abroad and are presently under clinical investigation in the United States. Sufentanil is more potent than fentanyl and is claimed to have fewer side effects and less variability in patient cardiovascular responses under stress. It appears that its primary application will be for high-dose narcotic anesthesia in patients with cardiovascular disease. Alfentanil has a shorter duration of action and is claimed to have less postoperative ventilatory depression than fentanyl. It is being recommended for use via continuous intravenous infusion. It will probably become a popular anesthetic agent for outpatient and short surgical procedures. It should be remembered that at this time very little information concerning these agents is in print. Most of the research has been done by a handful of investigators and much has not been published in peer review publications. Based on the clinical impressions of our European colleagues, one can say that these agents should be as safe and as reliable as fentanyl, but any clinically significant advantages over their parent compound, especially in the case of sufentanil, will have to await more widespread use and controlled investigation.</p>","PeriodicalId":75737,"journal":{"name":"Contemporary anesthesia practice","volume":"7 ","pages":"1-18"},"PeriodicalIF":0.0,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17202491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Balanced salt solutions as renal prophylaxis.","authors":"C A Baxter","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75737,"journal":{"name":"Contemporary anesthesia practice","volume":"6 ","pages":"137-50"},"PeriodicalIF":0.0,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17873514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There are many new neuromuscular blocking drugs now going through the clinical trials required before new drugs can be used clinically on a routine basis. It is safe to say that within the next five years the muscle relaxants now in common use will be replaced by new and more "ideal" muscle relaxants. This review has attempted to define for the practicing anesthesiologist the goals of muscle relaxant research and the drugs that have been developed from that research. It is hoped that some familiarity with these drugs before they become widely available may hasten their extensive use by practitioner in the interest of better anesthetic patient care.
{"title":"New muscle relaxants.","authors":"M R Fahey, R D Miller","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>There are many new neuromuscular blocking drugs now going through the clinical trials required before new drugs can be used clinically on a routine basis. It is safe to say that within the next five years the muscle relaxants now in common use will be replaced by new and more \"ideal\" muscle relaxants. This review has attempted to define for the practicing anesthesiologist the goals of muscle relaxant research and the drugs that have been developed from that research. It is hoped that some familiarity with these drugs before they become widely available may hasten their extensive use by practitioner in the interest of better anesthetic patient care.</p>","PeriodicalId":75737,"journal":{"name":"Contemporary anesthesia practice","volume":"7 ","pages":"61-81"},"PeriodicalIF":0.0,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17203155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号